Final results of phase II gimurell trial: The addition of Rituximab to dose-dense and high dose chemotherapy (HDC) with autologous transplantation (ASCT) improves the outcome of untreated poor-prognosis diffuse large B-cell lymphoma (DLBCL)

Authors :: ANNALISA CHIAPPELLA
Liberati, A. M.
Rossi, G.
Cabras, M. G.
Levis, A.
Pavone, V.
Angelucci, E.
Botto, B.
Ciccone, G.
Cortelazzo, S.
Falchi, L.
Freilone, R.
Gaidano, G.
Novero, D.
Pogliani, E. M.
Pregno, P.
Rota Scalabrini, D.
Salvi, F.
Tonso, A.
Tucci, A.
Gallo, E.
Vitolo, U.
Source :: Publons
Publication Year :: 2007

Tools